1616 completed, 544 terminated, 447 recruiting, 323 unknown. 3521 Phase 2, 986 Phase 1, 68 Phase 3.
Follow Neoplasms, Nerve Tissue: new trials by email Literature Review of Neoplasms, Nerve Tissue trials Research Report on Neoplasms, Nerve Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-11-06 |
| Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma Temozolomide (TMZ) - Cutaneous Melanoma | Phase 2 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 28 | 2027-06-01 | 2026-09-08 |
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| DLL3 CAR-T Therapy Targeting Brain Tumors 4SCAR DLL3 T cells - Glioblastoma of Cerebellum | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-11-02 |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-11-09 |
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma | Phase 2 | Not yet recruiting | Rapa Therapeutics LLC | 65 | 2027-03-01 | 2026-03-19 |
| Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2027-03-01 | 2026-09-09 |
| Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study Safusidenib - Glioma : Oligodendroglioma or Astrocytoma | Phase 2 | Not yet recruiting | University of Zurich | 20 | 2027-03-01 | 2026-09-21 |
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease Safusidenib - Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma | Phase 2 | Recruiting | Nuvation Bio Inc. | 40 | 2027-03-01 | 2026-10-20 |
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) Tovorafenib - High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV) | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 79 | 2027-02-01 | 2026-10-20 |
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Zanzalintinib in Unresectable and Progressive MPGGs Zanzalintinib - Pheochromocytoma, Paraganglioma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 14 | 2027-01-09 | 2026-07-20 |
| Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults Mirdametinib - LGCMN, Large and Giant Congenital Melanocytic Nevi | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2027-01-04 | 2026-10-29 |
Showing 20 of 3521. Sign in to see all of them.
Melanoma (1334) · Glioblastoma (881) · Glioma (456) · Brain Neoplasms (429) · Gliosarcoma (260) · Astrocytoma (258) · Neuroblastoma (246) · Central Nervous System Neoplasms (234) · Neuroendocrine Tumors (221) · Neoplasms (210) · Neoplasm Metastasis (190) · Carcinoma, Non-Small-Cell Lung (185) · Sarcoma (185) · Oligodendroglioma (160) · Uveal Melanoma (134)
Neoplasms by Histologic Type (3508) · Neuroectodermal Tumors (3366) · Neoplasms, Germ Cell and Embryonal (3364) · Neoplasms (3311) · Neoplasms by Site (2238) · Neoplasms, Glandular and Epithelial (1986) · Neuroendocrine Tumors (1650) · Neoplasms, Neuroepithelial (1549) · Nevi and Melanomas (1403) · Skin and Connective Tissue Diseases (1388) · Skin Diseases (1387) · Skin Neoplasms (1271) · Nervous System Diseases (823) · Glioma (810)
Temozolomide (419) · pembrolizumab (237) · Nivolumab (214) · Bevacizumab (203) · Radiotherapy (200) · Ipilimumab (177) · Cyclophosphamide (167) · Carboplatin (114) · aldesleukin (114) · Etoposide (84) · Magnetic Resonance Spectroscopy (84) · Irinotecan (83) · Interleukin-2 (82) · Cisplatin (81) · Everolimus (62)
National Cancer Institute (NCI) (330) · M.D. Anderson Cancer Center (98) · Memorial Sloan Kettering Cancer Center (82) · Dana-Farber Cancer Institute (43) · Duke University (43) · Novartis Pharmaceuticals (41) · H. Lee Moffitt Cancer Center and Research Institute (33) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (33) · Children's Oncology Group (31) · European Organisation for Research and Treatment of Cancer - EORTC (30) · Bristol-Myers Squibb (29) · University of California, San Francisco (26) · St. Jude Children's Research Hospital (25) · Hoffmann-La Roche (24) · Merck Sharp & Dohme LLC (24)
United States (2272) · France (297) · Canada (262) · Germany (248) · China (244) · Australia (237) · Spain (235) · Italy (232) · United Kingdom (222) · Netherlands (143) · Switzerland (135) · Belgium (126) · Denmark (78) · South Korea (78) · Austria (67)
Steven A Rosenberg, M.D. (22) · Steven A. Rosenberg, MD, PhD (21) · Stanislaw R. Burzynski, MD, PhD (20) · Annick Desjardins, MD, FRCPC (10) · Henry S. Friedman, MD (10) · Brian Kushner, MD (9)
PMID 31401903, PMID 36648215, PMID 25667295, PMID 22555974, PMID 23633099, PMID 37934000, PMID 23861247, PMID 24983357, PMID 25098701, PMID 28029918, PMID 32187457, PMID 32747469, PMID 34331515, PMID 34754076, PMID 39500789, PMID 39777725, PMID 40341199, PMID 12749708, PMID 15683544, PMID 16200343, PMID 17105749, PMID 17705175, PMID 19451433, PMID 21865400, PMID 21996156, PMID 22353803, PMID 22682017, PMID 23243055, PMID 23817721, PMID 24408395, PMID 25113840, PMID 25432172, PMID 26169613, PMID 26446943, PMID 26851632, PMID 27580889, PMID 28230061, PMID 28409229, PMID 28592387, PMID 29412784, PMID 31010905, PMID 31406564, PMID 31582003, PMID 31838007, PMID 32691060, PMID 33354735, PMID 33607632, PMID 33863389, PMID 33990415, PMID 34132224
2023 (39), U10CA180886 (34), U10CA098543 (26), 2014 (23), 2018 (22), 2016 (21), 2019 (20), 2015 (19), 2009 (17), P30CA008748 (16), U10CA032102 (15), 2017 (14), 2025 (14), U01CA062475 (14), U10CA180821 (14)